Great news yesterday as we heard that the drug advisers have changed guidance on Lenalidomide, also known as Revlimid. Revised draft guidance has agreed access to the treatment for myeloma sufferers, under a cost -sharing deal where the drug company will pick up the cost after two years. This is the first guidance from NICE to be revised after the new rules, designed to be more flexible in judging treatments, offering survival benefits in terminal conditions. This latest recommendation is out for consultation until the 20th February.
You can read the more on http://news.bbc.co.uk/1/hi/health/7859053.stm and also more from the wonderful http://www.myeloma.co.uk/ who have fought so hard for this to come about.
It is indeed the most wonderful news.
Best wishes. We are thinking of you. Love & Prayers
I have also blogged about this. I hope it makes a difference for Hamada. However, the same deal does NOT apply to the NHS in Scotland, where they are applying the “greater good for the greater number” rule. Sigh.
I was saddened to read that Scotland is to take this view. Perhaps, when hopefully – fingers crossed always – this arrangement with the drug companies is up and running, they will see the error of their ways – I sincerely hope they do.
Susie, this is wonderful! I’m hopeful for you and Hamada. Being connected with others not just in the US, with Myeloma, has brought home how desperate it can be.
I’m just really happy that you will have something new to try.
Thanks Lori. I have been so pleased to read of David’s success.. he seems to be doing so very well… all the best to you both and good luck for your return visit, I sincerely hope all goes well.
Revlimid is SUCH an effective drug. I do so hope that Hamada will be able to take it. Prayers for you both.